Intuitive Surgical 10-Qquarter ended 2026-03-31

Executive Summary

Intuitive Surgical’s Q1 2026 growth came from more procedures on its installed systems, increased da Vinci 5 placements, and faster expansion outside the U.S. Revenue rose 23% year over year, while operating income rose 48% as product margins improved and operating expenses grew more slowly than sales. Recurring revenue reached 86% of the total, strengthening the link between the installed base and future sales; however, tariffs, hospital spending constraints, and rising service costs could temper that operating leverage. The company generated substantial cash while funding a European distribution acquisition and repurchases, though the buyback reduced shares outstanding by far less than the number purchased.

Key Financial Highlights

Q1 ended 3/31/2026; for this filing, Q1 is also YTD.

• Revenue mix: Instruments and accessories $1.69B, +23% Y/Y; systems $651M, +25%; services $434M, +20%. Recurring revenue was $2.37B, or 86% of revenue, versus 85% a year earlier.
• Cash conversion: OCF $912M vs net income attributable to Intuitive Surgical of $822M; capital expenditures $103M → FCF $809M. Noncash charges of $731M more than offset a $645M working-capital cash use, including inventory growth and prepaid taxes.
• Capital return: Repurchases of $1.13B bought 2.3M shares, while shares outstanding fell only 0.7M, from 355.1M to 354.4M. Stock-based compensation expense before tax was $213M, up from $190M.
• Earnings comparison: Income tax expense was $114M vs a $35.2M benefit a year earlier; the stronger operating result was partly obscured at the net-income line.

Business Developments

Da Vinci procedures increased 16% to ≈847,000, and utilization per system rose 3%. Intuitive placed 431 da Vinci systems vs 367, including 232 da Vinci 5 systems vs 147; the installed base grew 12% to ≈11,395. Together, procedure growth and a larger installed base expand the opportunity for instruments, accessories, and services revenue. Higher da Vinci 5 sales also helped lift the average selling price to ≈$1.74M from ≈$1.62M.

Outside-U.S. revenue grew 38% to $988M, reaching 36% of total revenue from 32%; currency movements contributed a favorable $36M. On 3/1/2026, Intuitive acquired da Vinci and Ion distribution businesses in Italy, Spain, Portugal, and nearby territories for ≈$533M in cash. Management is transitioning those markets to direct sales, increasing its control of customer relationships as international procedures grow.

Ion procedures rose ≈39% to 42,700, while its installed base grew 22% to ≈1,041. U.S. Ion placements declined as some customers emphasized use of existing systems over new capacity. Clearances for additional da Vinci 5 and SP uses, and for Ion navigation software incorporating artificial intelligence, broaden the portfolio; converting those capabilities into sustained procedure growth remains the commercial test.

Risk Assessment

• Tariffs and supply costs: Trade measures added ≈$28M to Q1 cost of revenue; further changes or supplier pass-through could erode product margins.
• Hospital spending and credit: Staffing, reimbursement, inflation, and borrowing-cost pressures could slow procedures or system purchases and increase losses on lease and trade receivables.
• International execution: China quotas, tender delays, competition, and reimbursement limits constrain placements and pricing; faster outside-U.S. growth also increases currency exposure.
• Service and lease economics: Service margin fell to 63.0% from 65.6%, while greater use of operating and usage-based leases shifts some revenue recognition over time and ties collections more closely to customer activity.
• Litigation: Product-liability claims and commercial antitrust matters could produce costs above current accruals; potential excess losses cannot currently be estimated.

This 10-Q lists no risk factors of its own and refers to the annual report. The risks above come from the rest of this filing. Full list: FY2025 10-K.

Strategic Outlook and Investor Actionables

Intuitive is investing in da Vinci 5, Ion, SP, digital capabilities, and direct international distribution to turn a growing installed base into recurring procedure-related revenue. The near-term investment case rests on sustained procedure growth and product margin gains overcoming tariffs, service costs, and higher expected depreciation and acquired-intangible amortization.

• Procedure demand: Track da Vinci procedure growth and utilization against installed-base growth; slowing use per system would weaken the recurring-revenue thesis.
• Placement quality: Track da Vinci 5 placements, Ion utilization, and operating-lease mix; stronger placements without corresponding procedure growth would defer the economic payoff.
• Margin and cash discipline: Track product and service margins, OCF, and shares outstanding; tariff or service-cost pressure, or repurchases that fail to reduce the share count, would weaken returns from growth.